SCHEMBL6171844

SCHEMBL6171844

Nc1cc(C(=O)NS(=O)(=O)c2ccccc2)ccc1[N+](=O)[O-]

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.59
FBP1 P09467 5/20 0.55
MEN1 O00255 1/20 0.55
LMNA P02545 1/20 0.55
KMT2A Q03164 1/20 0.55
FFAR4 Q5NUL3 1/20 0.51
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
FLT1 P17948 3/20 0.49
FLT4 P35916 3/20 0.49
KDR P35968 3/20 0.49
GAA P10253 1/20 0.48
P4HTM Q9NXG6 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
BCL2L1 Q07817 3/20 0.48
MCL1 Q07820 3/20 0.48
BCL2 P10415 2/20 0.48
PTPN1 P18031 1/20 0.46
EGFR P00533 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11485510 0.79 MEN1 (0.68) MAPK1MEN1LMNAKMT2AGAA
SCHEMBL6169323 0.78 POLB (0.56) MAPK1FBP1LMNAKMT2AGAA
SCHEMBL8654939 0.78 FLT1 (0.76) MEN1LMNAKMT2APTGS1PTGS2
SCHEMBL8304862 0.77 GAA (0.76) MEN1LMNAKMT2AFLT1FLT4
SCHEMBL27490824 0.76 HDAC8 (0.52) FBP1MEN1LMNAKMT2AL3MBTL1
SCHEMBL5931288 0.75 FLT1 (0.71) MEN1LMNAKMT2APTGS1PTGS2
SCHEMBL11014246 0.75 MAPK1 (1.00) MAPK1MEN1LMNAKMT2AL3MBTL1
SCHEMBL6168810 0.75 HDAC8 (0.51) FBP1MEN1LMNAKMT2AL3MBTL1
SCHEMBL6168346 0.74 KMT2A (0.51) MEN1LMNAKMT2APTGS1PTGS2
SCHEMBL8660071 0.74 MEN1 (0.87) MEN1LMNAKMT2APTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6211177-B1 SIDE EFFECT REDUCTION CELL PATHWAYS, INC. 2001-04-03 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed